02256.HK
Abbisko Cayman Limited
HKSE · Healthcare · Biotechnology · CN
HKD 6.19
−2.37%Sep 21, 2026, 00:48 UTC
Hutchmed's subsidiary Shanghai Hutchison announced positive preliminary Phase II clinical results for its oral FGFR2/3 inhibitor lavengratinib (ABSK061) in children with achondroplasia.
Source:Sep 21, 2026, 00:44 UTC
Shanghai Abbisko Therapeutics announced positive preliminary Phase II results for its oral FGFR2/3 inhibitor lavengratinib (ABSK061) in children with achondroplasia, with a 100% response rate and mean annualized height velocity increase of +2.4 cm/year at the lowest dose.
Aug 24, 2026, 18:06 UTC
Abbisko Therapeutics reported an interim net loss of 193 million RMB for the six months ended June 2026, swinging from a profit of 328 million RMB a year earlier, with revenue down 84.1% to 97.27 million RMB.
Source:Jun 24, 2026, 01:38 UTC
Abbisko Therapeutics entered into a strategic research collaboration and license agreement with Eli Lilly.
Source: